Table 2 Anemia response in transfusion-dependent and non-transfusion-dependent patients, subdivided by prior exposure to JAKi.

From: Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study

n = 122*

TDA (all)

n = 90

JAKi exposed TDA

n = 71

JAKi naïve TDA

n = 19

Non-TDA

 n = 32

JAKi exposed non-TDA

n = 24

JAKi naïve non-TDA

n = 8

Median Hb (IQR), [range]

7.7 (1.375) [4.7-9.8]

7.6 (1.5) [4.7-9.8]

8 (0.8) [5.8-9.4]

8.9 (1.175) [7.2-10.8]

8.9 (1.45) [7.2-10.8]

8.8 (0.65) [8-10.4]

Median RBC/month (IQR), [range]

4 (3) [1–8]

3 (3) [1–8]

4 (2.75) [1–8]

N/A

N/A

N/A

Last follow up (n = 124)

n = 90

n = 71

n = 19

n = 32

n = 24

n = 8

Median Hb (IQR), [range]

8.55 (1.775) [5-12.6]

8.6 (1.9) [5-12.6]

8.5 (1.2) [7-11.5]

10.2 (2.325) [6.5-17.2]

10.85 (2.325) [7.9-17.2]

9.1 (1.7) [6.5-10.2]

Median RBC/month (IQR), [range]

1 (3) [0-16]

0.75 (2.375) [0-16]

2 (2.5) [0-6]

N/A

N/A

N/A

Major response

23 (25.6)

21 (29.6)

2 (10.5)

14 (43.8)

14 (58.3)

0 (0)

Minor response

32 (35.6)

25 (35.2)

7 (36.8)

3 (9.4)

2 (8.3)

1 (12.5)

No minor or major response

29 (32.2)

20 (28.2)

9 (47.4)

15 (46.9)

8 (33.3)

7 (87.5)

ND

6 (6.7)

5 (7.0)

1 (5.3)

0 (0)

0 (0)

0 (0)

3 months follow-up (n = 90)

n = 67

n = 55

n = 12

n = 23

n = 17

n = 6

Median Hb (IQR), [range]

8.7 (1.55) [6.3-13]

8.6 (1.65) [6.3–13]

9.1 (1.175) [6.8–10.2]

10.2 (2.1) [8.1–17.2]

10.5 (1.5) [8.1–17.2]

9.05 (0.95) [8.3–10.6]

Median RBC/month (IQR), [range]

1 (3) [0-8]

0.5 (2.75) [0–8]

2 (2.775) [0–5]

N/A

N/A

N/A

Major response

18 (26.9)

16 (29.1)

2 (16.7)

11 (47.8)

10 (58.8)

1 (16.7)

Minor response

21 (31.3)

17 (30.9)

4 (33.3)

2 (8.7)

2 (11.8)

0 (0)

No minor or major response

21 (31.3)

16 (29.1)

5 (41.7)

10 (43.5)

5 (29.4)

5 (83.3)

ND

7 (10.4)

6 (10.9)

1 (8.3)

0 (0)

0 (0)

0 (0)

6 months follow-up (n = 47)

n = 36

n = 28

n = 8

n = 11

n = 7

n = 4

Median Hb (IQR), [range]

8.75 (2.05) [6–12.1]

8.6 (2.125) [6–12.1]

8.95 (1.275) [7–10.2]

10.1 (2.4) [7.7–12.5]

11 (2.25) [9-12.5]

9.25 (0.975) [7.7-–10.1]

Median RBC/month (IQR), [range]

1 (3) [0-16]

0.75 (2.75) [0-16]

1.65 (3.125) [0-6]

N/A

N/A

N/A

Major response

11 (30.6)

9 (32.1)

2 (25)

4 (36.4)

4 (57.1)

0 (0)

Minor response

13 (36.1)

10 (35.7)

3 (37.5)

3 (27.3)

2 (28.6)

1 (25)

No minor or major response

9 (25)

6 (21.4)

3 (37.5)

4 (36.4)

1 (14.2)

3 (75)

ND

3 (8.3)

3 (10.7)

0 (0)

0 (0)

0 (0)

0 (0)

  1. *The analysis included patients with anemia per the 2024 IWG-ELN criteria who had at least one month of follow-up for response evaluation. n: Number of patients, m: months, TDA Transfusion-Dependent Anemia, JAKi Janus Kinase Inhibitor, Hb: Hemoglobin, IQR Interquartile Range, RBC Red Blood Cells, N/A Not Applicable, ND No Data.
Back to article page